News, views and contacts from the global Drugdevelopment industry
17 August 2017
Digital Magazine
Latest Companies

SYSTAG Systems Technik - Automation Systems for Small-Molecule Drug and API Development

Pharmatest Services - Research Models to Evaluate Drug Candidate Efficacy

ImmunoPrecise Antibodies - Custom Monoclonal and Polyclonal Antibody Development

Pharmaceutical Development Group - Pharmaceutical Consultant and FDA Regulatory Strategist

Biovian - Contract Manufacturing Of Biopharmaceuticals

Press Releases

Gamlen Appoints ABL&E as Distributor
Gamlen Instruments has appointed ABL&E as the exclusive distributor for Gamlen Instruments in Eastern Europe.

Powerful Benchtop Spectrometer for Small Spot Analysis
Supplier of analytical X-ray instrumentation and software PANalytical has announced the introduction of a new Epsilon 1 X-ray fluorescence (XRF) spectrometer.

Huge New Opportunity in Generic Drug Development Created by US FDA
The US market is to gain access to previously unavailable therapeutically equivalent generic drug formulations due to a number of changes.

Tailoring the Properties of New Compounds Using XRD Data Analysis
Understanding the make-up of crystalline structures is a vital aspect of the characterisation of new compounds, and can be regarded as an important first step towards the possibility of tailoring its properties.

Upcoming Events Malvern
Malvern will be hosting a wide range of webinars throughout July and August.

White Papers

Softigel by Procaps Brochure
Procaps is one of the world's largest softgel companies, specialising in the production and development of advanced gelatin-related...

The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days
The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18...

Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs
Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer....

Processability Assessment of Crystal Habit-Modified Active Pharmaceutical Ingredients
The efficiency of downstream processing of active pharmaceutical ingredients (API) can depend on their particulate properties, including size and shape....

Gold Nanoparticle Applications and Characterisation by Nanoparticle Tracking Analysis
Gold nanoparticles are one of the most popular and extensively researched type of...


July’s top stories: NCI and COG’s paediatric precision cancer trial, AstraZeneca’s NSCLC trial results
NIH’s unit NCI and the COG initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines, and AstraZeneca reported positive results from the FLAURA trial of Tagrisso to treat patients with locally advanced or metastatic NSCLC. Drugdevelopment-technology.com wraps up the key headlines from July.

June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic kidney disease. Drugdevelopment-technology.com wraps up the key headlines from June.

May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II
Medical research funders and international NGOs agreed to implement the new WHO standards for clinical trials, and Actinogen Medical began patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s disease. Drugdevelopment-technology.com wraps up the key headlines from May.

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial
The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of nintedanib to treat various progressive fibrosing lung diseases. Drug development-technology.com wraps up the key headlines from April.

March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis
Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of psoriasis. Drugdevelopment-technology.com wraps up the key headlines from March.


MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C
MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection
Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis
Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis.

Endari for the Treatment of Sickle Cell Disease
Endari™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease.

Haegarda for the Preventive Treatment of Hereditary Angioedema
Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.